BeyondSpring Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
BeyondSpring Inc. (BYSI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $389.00 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2023-04-18.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2023-04-18
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2022-12-31 | $389.00K 20-F · filed 2023-04-18 |
| 2021-12-31 | $0.00 20-F · filed 2023-04-18 |
| 2020-12-31 | $0.00 20-F · filed 2023-04-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |